首页> 外文OA文献 >Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections
【2h】

Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections

机译:病例对照文献的多分析物分析用于抑郁症和精神分裂症的血浆蛋白生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite significant research efforts aimed at understanding the neurobiological underpinnings of psychiatric disorders, the diagnosis and the evaluation of treatment of these disorders are still based solely on relatively subjective assessment of symptoms. Therefore, biological markers which could improve the current classification of psychiatry disorders, and in perspective stratify patients on a biological basis into more homogeneous clinically distinct subgroups, are highly needed. In order to identify novel candidate biological markers for major depression and schizophrenia, we have applied a focused proteomic approach using plasma samples from a large case-control collection. Patients were diagnosed according to DSM criteria using structured interviews and a number of additional clinical variables and demographic information were assessed. Plasma samples from 245 depressed patients, 229 schizophrenic patients and 254 controls were submitted to multi analyte profiling allowing the evaluation of up to 79 proteins, including a series of cytokines, chemokines and neurotrophins previously suggested to be involved in the pathophysiology of depression and schizophrenia. Univariate data analysis showed more significant p-values than would be expected by chance and highlighted several proteins belonging to pathways or mechanisms previously suspected to be involved in the pathophysiology of major depression or schizophrenia, such as insulin and MMP-9 for depression, and BDNF, EGF and a number of chemokines for schizophrenia. Multivariate analysis was carried out to improve the differentiation of cases from controls and identify the most informative panel of markers. The results illustrate the potential of plasma biomarker profiling for psychiatric disorders, when conducted in large collections. The study highlighted a set of analytes as candidate biomarker signatures for depression and schizophrenia, warranting further investigation in independent collections.
机译:尽管为了解精神疾病的神经生物学基础付出了巨大的努力,但是对这些疾病的诊断和治疗评估仍仅基于症状的相对主观评估。因此,迫切需要能够改善当前精神病学分类并从生物学角度将患者分层为临床上更均一的亚组的生物学标记物。为了确定主要的抑郁症和精神分裂症的新型候选生物学标记,我们使用了来自大型病例对照集合的血浆样本,采用了聚焦蛋白质组学方法。使用结构化访谈,根据DSM标准诊断了患者,并评估了许多其他临床变量和人口统计学信息。对来自245名抑郁症患者,229名精神分裂症患者和254名对照的血浆样品进行了多分析物分析,从而可以评估多达79种蛋白质,包括先前建议与抑郁症和精神分裂症的病理生理有关的一系列细胞因子,趋化因子和神经营养蛋白。单变量数据分析显示p值比偶然预期的要重要,并且强调了一些蛋白质,这些蛋白质先前被怀疑与重度抑郁症或精神分裂症的病理生理有关,例如胰岛素和抑郁症的MMP-9,以及BDNF ,EGF和多种趋化因子用于精神分裂症。进行多变量分析以改善病例与对照的区别,并鉴定出最具信息量的标志物。结果表明,在大量收集中进行时,血浆生物标志物谱分析可用于治疗精神疾病。这项研究突出了一组分析物作为抑郁症和精神分裂症的候选生物标志物特征,有必要在独立的馆藏中进行进一步的研究。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号